Arsenic methylation, GSTO1 polymorphisms, and metabolic syndrome in an arseniasis endemic area of southwestern Taiwan

Chemosphere

Volumn 88, Issue 4, 2012, Pages 432-438

  Chen, Jein Wen ^a   Wang, Shu Li ^a,b   Wang, Ya Hui ^a   Sun, Chien Wen ^a   Huang, Yeou Lih ^c   Chen, Chien Jen ^d   Li, Wan Fen ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

Author keywords

Arsenic; Metabolic syndrome; Methylation; Risk factor; Type 2 diabetes mellitus

Indexed keywords

ALKYLATION; GENES; METABOLISM; METHYLATION; POLYMORPHISM;

ARSENIC CONCENTRATION; DIMETHYLARSINIC ACIDS; GENETIC POLYMORPHISMS; INORGANIC ARSENIC; METABOLIC SYNDROMES; MONOMETHYLARSONIC ACIDS; RISK FACTORS; TYPE 2 DIABETES MELLITUS;

ARSENIC;

ARSENIC; METHANEARSONIC ACID;

ALLELE; ARSENIC; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; GENETIC ANALYSIS; METABOLISM; METHYLATION; ORGANIC ACID; POLLUTION EXPOSURE; POLYMORPHISM; RECRUITMENT (POPULATION DYNAMICS); RISK FACTOR;

ADULT; AGED; ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); DNA POLYMORPHISM; FEMALE; FLUID INTAKE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METHYLATION; RISK ASSESSMENT; RURAL POPULATION; TAIWAN; URINALYSIS; URINE LEVEL; WATER CONTAMINATION;

TAIWAN;

EID: 84862791554     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2012.02.059     Document Type: Article

References (40)

1. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet. Med. 2006, 23:469-480.
2. Aposhian H.V., Aposhian M.M. Arsenic toxicology: five questions. Chem. Res. Toxicol. 2006, 19:1-15.
3. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995, 25:53-60.
4. Chen J.W., Chen H.Y., Li W.F., Liou S.H., Chen C.J., Wu J.H., Wang S.L. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere 2011, 84:17-24.
5. Chiu H.F., Chang C.C., Tsai S.S., Yang C.Y. Does arsenic exposure increase the risk for diabetes mellitus?. J. Occup. Environ. Med. 2006, 48:63-67.
6. Chung C.J., Hsueh Y.M., Bai C.H., Huang Y.K., Huang Y.L., Yang M.H., Chen C.J. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Contr. 2009, 20:1653-1661.
7. Cohen D., Stolk R.P., Grobbee D.E., Gispen-de Wied C.C. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006, 29:786-791.
8. Coronado-Gonzalez J.A., Del Razo L.M., Garcia-Vargas G., Sanmiguel-Salazar F., Escobedo-de la Pena J. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ. Res. 2007, 104:383-389.
9. Das P.M., Sadana J.R., Gupta P.K., Kumar K. Experimental selenium toxicity in guinea pigs: biochemical studies. Ann. Nutr. Metab. 1989, 33:57-63.
10. Del Razo L.M., Garcia-Vargas G.G., Garcia-Salcedo J., Sanmiguel M.F., Rivera M., Hernandez M.C., Cebrian M.E. Arsenic levels in cooked food and assessment of adult dietary intake of arsenic in the Region Lagunera, Mexico. Food Chem. Toxicol. 2002, 40:1423-1431.
11. Fu J., Woods C.G., Yehuda-Shnaidman E., Zhang Q., Wong V., Collins S., Sun G., Andersen M.E., Pi J. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ. Health Perspect. 2010, 118:864-870.
12. Guha Mazumder D.N. Chronic arsenic toxicity and human health. Indian J. Med. Res. 2008, 128:436-447.
13. Hopenhayn-Rich C., Biggs M.L., Smith A.H., Kalman D.A., Moore L.E. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ. Health Perspect. 1996, 104:620-628.
14. Izquierdo-Vega J.A., Soto C.A., Sanchez-Pena L.C., De Vizcaya-Ruiz A., Del Razo L.M. Diabetogenic effects and pancreatic oxidative damage in rats subchronically exposed to arsenite. Toxicol. Lett. 2006, 160:135-142.
15. Kuo, T.L., 1964. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning, in Reports of insulin of pathology. National Taiwan University College of Medicine, Taipei, Taiwan 7-13.
16. Lin S., Shi Q., Nix F.B., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., Thomas D.J. A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 2002, 277(13):10795-10803.
17. Marahatta S.B., Punyarit P., Bhudisawasdi V., Paupairoj A., Wongkham S., Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett. 2006, 236:276-281.
18. Mass M.J., Tennant A., Roop B.C., Cullen W.R., Styblo M., Thomas D.J., Kligerman A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 2001, 14:355-361.
19. Nabi A.H., Rahman M.M., Islam L.N. Evaluation of biochemical changes in chronic arsenic poisoning among Bangladeshi patients. Int. J. Environ. Res. Public Health 2005, 2:385-393.
20. National Research Council, 1999. Risk assessment of arsenic in drinking water. Subcommittee on arsenic in drinking water. National Academy Press, Washington DC, pp. 263.
21. Navas-Acien A., Silbergeld E.K., Streeter R.A., Clark J.M., Burke T.A., Guallar E. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ. Health Perspect. 2006, 114:641-648.
22. Navas-Acien A., Silbergeld E.K., Pastor-Barriuso R., Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 2008, 300:814-822.
23. Nordstrom D.K. Worldwide occurrences of arsenic in ground water. Science 2002, 296:2143-2145.
24. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 2000, 163:203-207.
25. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., Hoefle G., Drexel H. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006, 29:901-907.
26. Smith A.H., Lopipero P.A., Bates M.N., Steinmaus C.M. Arsenic epidemiology and drinking water standards. Science 2002, 296:2145-2146.
27. Suk W.A., Ruchirawat K.M., Balakrishnan K., Berger M., Carpenter D., Damstra T., de Garbino J.P., Koh D., Landrigan P.J., Makalinao I., Sly P.D., Xu Y., Zheng B.S. Environmental threats to children's health in Southeast Asia and the Western Pacific. Environ. Health Perspect. 2003, 111:1340-1347.
28. Tchounwou P.B., Patlolla A.K., Centeno J.A. Carcinogenic and systemic health effects associated with arsenic exposure-a critical review. Toxicol. Pathol. 2003, 31:575-588.
29. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 2007, 232:3-13.
30. Thompson D.J. A chemical hypothesis for arsenic methylation in mammals. Chem. Biol. Interact. 1993, 88:89-114.
31. Tseng C.H. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol. Appl. Pharmacol. 2004, 197:67-83.
32. Tseng C.H. A review on environmental factors regulating arsenic methylation in humans. Toxicol. Appl. Pharmacol. 2009, 235:338-350.
33. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol. Lett. 2000, 112-113:209-217.
34. Wang S.L., Pan W.H., Hwu C.M., Ho L.T., Lo C.H., Lin S.L., Jong Y.S. Incidence of NIDDM and the effects of gender, obesity and hyperinsulinaemia in Taiwan. Diabetologia 1997, 40:1431-1438.
35. Wang S.L., Chiou J.M., Chen C.J., Tseng C.H., Chou W.L., Wang C.C., Wu T.N., Chang L.W. Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwan. Environ. Health Perspect. 2003, 111:155-159.
36. Wang S.L., Chang F.H., Liou S.H., Wang H.J., Li W.F., Hsieh D.P. Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of Taiwan. Environ. Int. 2007, 33:805-811.
37. Wannamethee S.G., Shaper A.G., Lennon L., Morris R.W. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 2005, 165:2644-2650.
38. Wen C.P., Cheng T.Y., Tsai S.P., Hsu H.L., Wang S.L. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005, 28:2756-2761.
39. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
40. Zakharyan R.A., Sampayo-Reyes A., Healy S.M., Tsaprailis G., Board P.G., Liebler D.C., Aposhian H.V. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 2001, 14(8):1051-1057.